New drug combo aims to stop pancreatic cancer from coming back after surgery
NCT ID NCT07277452
First seen Jan 10, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This study tests whether adding nimotuzumab to standard chemotherapy (nab-paclitaxel and gemcitabine) before and after surgery can help prevent pancreatic cancer from returning. About 156 adults with high-risk or borderline resectable pancreatic cancer will take part. The goal is to see if the combination improves how long people stay cancer-free after surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER, ADULT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chunyi Hao
Beijing, 100000, China
Contact
Contact
-
Kuirong Jiang
Nanjing, Jiangsu, 210029, China
Contact
Conditions
Explore the condition pages connected to this study.